Shenzhen Hepalink Pharmaceutical Group Co., Ltd.

Research Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (9989.HK) on Bullrun: market cap HKD 5.81B, P/E 26.4, dividend yield 4.1%. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is HKD 5.81B; P/E is 26.4; dividend yield is 4.1%.

Peer valuation comparison

Latest P/E is 26.4x versus a Healthcare sector median of 21.8x (21.1% above).

Latest dividend yield is 4.14% versus a Healthcare sector median of 2.4% (72.5% above).

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-10-18HKD 5.81B26.44.2%0.17

Dividend history

Latest trailing dividend snapshot: annual dividend/share 0.17 HKD, yield 4.1%.

About Shenzhen Hepalink Pharmaceutical Group Co., Ltd.

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. provides pharmaceutical products in Hong Kong, the United States, Europe, Mainland China, and internationally. It operates in four segments: Pharmaceutical preparations, Active Pharmaceutical Ingredients (API), Contract Development and Manufacturing Organization (CDMO), and Others. The company offers pharmaceutical preparations products, such as enoxaparin sodium injection; API products, including heparin and enoxaparin sodium APIs.

ETFs that hold Shenzhen Hepalink Pharmaceutical Group Co., Ltd.

US-listed ETFs

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. is held by 14 US-listed ETFs, going by the latest portfolios they filed with the SEC. The 8 most traded of them:

ETFWeightFee
Vanguard Total International Stock Index Fund ETF Shares (VXUS)<0.01%0.05%
Vanguard FTSE Emerging Markets Index Fund ETF Shares (VWO)<0.01%0.06%
Vanguard Total World Stock Index Fund ETF Shares (VT)<0.01%0.06%
Vanguard FTSE All-World ex-US Index Fund ETF Shares (VEU)<0.01%0.04%
State Street SPDR Portfolio Emerging Markets ETF (SPEM)<0.01%0.07%
Dimensional Emerging Core Equity Market ETF (DFAE)<0.01%0.29%
Dimensional Emerging Markets Core Equity 2 ETF (DFEM)<0.01%0.39%
Dimensional World ex U.S. Core Equity 2 ETF (DFAX)<0.01%0.28%

Portfolios as filed with the SEC on Form N-PORT, dated June to July 2026. Brokers in the EU generally do not offer US-listed ETFs to retail investors.

Related stock research

China stocks China Healthcare stocks A-Z stock index

Other Healthcare stocks

Shandong Dong-Ee Jiao Co Ltd (000423.SZ) Livzon Pharmaceutical Group Inc (000513.SZ) Yunnan Baiyao Group Co., Ltd. (000538.SZ) Jilin Aodong Pharmaceutical Group Co., Ltd. (000623.SZ) Chang Chun High and New Technology Industry (Group) Inc. (000661.SZ) Apeloa Pharmaceutical Co., Ltd. (000739.SZ) Huadong Medicine Co Ltd (000963.SZ) China Resources Sanjiu Medical & Pharmaceutical Co Ltd (000999.SZ) Zhejiang NHU Co Ltd (002001.SZ) Jiangsu Nhwa Pharmaceutical Co Ltd (002262.SZ) Shijiazhuang Yiling Pharmaceutical Co Ltd (002603.SZ) Chengdu Kanghong Pharmaceutical Group Co., Ltd (002773.SZ)

Frequently asked questions

What is Shenzhen Hepalink Pharmaceutical Group Co., Ltd.'s market cap?

Shenzhen Hepalink Pharmaceutical Group Co., Ltd.'s market capitalization is HKD 5.81B.

What is Shenzhen Hepalink Pharmaceutical Group Co., Ltd.'s P/E ratio?

Shenzhen Hepalink Pharmaceutical Group Co., Ltd.'s price-to-earnings (P/E) ratio is 26.4.

Does Shenzhen Hepalink Pharmaceutical Group Co., Ltd. pay a dividend?

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. has a dividend yield of 4.1%.

What does Shenzhen Hepalink Pharmaceutical Group Co., Ltd. do?

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. provides pharmaceutical products in Hong Kong, the United States, Europe, Mainland China, and internationally. It operates in four segments: Pharmaceutical preparations, Active Pharmaceutical Ingredients (API), Contract Development and Manufacturing Organization (CDMO), and Others. The company offers pharmaceutical preparations products, such as enoxaparin sodium injection; API products, including heparin and enoxaparin sodium APIs.